(19) Europäisches Patentamt
European Patent Office
Office européen des brevets

(11) EP 0 816 916 A1

(12) EUROPEAN PATENT APPLICATION

(43) Date of publication:
07.01.1998 Bulletin 1998/02

(51) Int Cl.6: **G03C 5/30**

(21) Application number: **97420091.7**

(22) Date of filing: **17.06.1997**

(84) Designated Contracting States:
AT BE CH DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

(30) Priority: **24.06.1996 FR 9608149**

(71) Applicant: **EASTMAN KODAK COMPANY**
Rochester, New York 14650-2201 (US)

(72) Inventors:
- **Roussilhe, Jacqes, Kodak Industrie**
  71102 Chalon Sur Saone Cedex (FR)
- **Tsoi, Siu-Chung**
  Watford, Hertfordshire WD1 3AG (GB)

(74) Representative: **Parent, Yves et al**
KODAK INDUSTRIE
Département Brevets - CRT
Zone Industrielle
B.P. 21
71102 Chalon-sur-Saône Cédex (FR)

(54) Photographic developing composition

(57) The present invention concerns a developer for silver halide photographic products comprising a co-developer of the 1-phenyl-3-pyrazolidinone type.

These co-developers comprising solubilising groups which are not attached directly to the phenyl ring or the pyrazolidine ring.

These co-developers improve the stability of the developers.



Fig. 1

EP 0 816 916 A1

Description

The present invention concerns photography and novel compounds of the 3-pyrazolidinone type used for the development of silver halide photographic products, in particular as co-developing agents for developing black and white photographic films or papers.

Developing agents are described in Chimie et Physique Photographiques, P Glafkides, Chapter IX, pages 152-170, fifth edition. In general a main developing agent is used in association with an auxiliary developing agent. In certain cases, a synergetic effect is observed between the main developing agent, referred to hereinafter as the "developing agent", and the auxiliary developer or "co-developin agent". That is to say, the combined activity of the mixture of these two agents is greater than the sum of the activities of each of these agents used separately in the same solution. This phenomenon, called "superadditivity", is explained in Mason, "Photographic Processing Chemistry", Focal Press, London, 1975.

Polyphenols, for example hydroquinone, and reductones, for examples compounds of the ascorbic acid type, are the most widely used developers in practice in black and white developing solutions.

The most frequently used co-developing agents include aminophenols, such as Elon® (methyl-p-aminophenol sulfate), 1-phenyl-3-pyrazolidinones or Phenidones, such as Phenidone-A (1-phenyl-3-pyrazolidinone), Phenidone-B (1-phenyl-4 methyl-3-pyrazolidinone), Dimezone (1-phenyl-4,4'dimethyl-3-pyrazolidinone), Dimezone-S (1-phenyl-4-methyl-4'-hydroxymethyl-3-pyrazolidinone). Additional representative examples of aminophenols and phenidones are described in US patents 2 688 549, 2 691 589, 3 865 591, 4 269 929, 4 840 879 and 5 236 816, and by G E Ficken and B G Sanderson, The Journal of Photographic Science, Vol 11, 1963, pages 157-164.

Co-developing agents with improved solubility in water are desirable in order to facilitate the manufacture of the developer, or its ease of use. In particular, photographic processing solutions are often packaged in the form of powders to be dissolved in water or concentrated liquids to be diluted before use. These concentrates must be easily soluble.

European patent 0 528 480 describes a radiographic product comprising a 3-pyrazolidinone substituted by a carboxy group directly attached to the phenyl ring. This compound is used as an anti-fog agent. The radiographic product is developed with a conventional developer comprising hydroquinone and a 1-phenyl-pyrazolidine-1-one co-developing agent.

In view of the low solubility of Phenidone or Dimezone-S, US patent 4 753 869 proposed that these 1-phenyl-3-pyrazolidinones be prepared in the form of salts of four particular acids including sulfo groups which dissolve easily in water and are stable during storage. The activity of these compounds in combination with hydroquinone is said to be comparable with that of pyrazolidinones which are not in the form of salts.

In Zhurnal Nauchnoi i Prikladnoi Fotografii i kinematografii 10, (5), 321-329 (1963) V L Abritalin et al describe photographic developers comprising hydroquinone and very many derivatives of 3-pyrazolidinones, some of which have solubilizing groups fixed directly on the benzene ring. According to this article, the introduction of solubilizing carboxy or sulfo groups to the benzene ring reduces the superadditivity of phenidone/hydroquinone mixtures. This tendency is also noted by G E Ficken and B G Sanderson, in The Journal of Photographic Science, Vol 11, 1963, pages 157-160, who reports that the introduction of a carboxylic group to the phenidone reduces the superadditivity of the Phenidone/hydroquinone mixtures.

Developers based on hydroquinone generally yield good results but require the use of high pH. That is why ascorbic acid has been recommended instead of hydroquinone.

US patent 5 098 819 describes a developing combination comprising ascorbic acid or a derivative thereof, and a 3-pyrazolidinone. The developers in the examples contain sodium erythorbate, Phenidone or Dimezone-S and potassium carbonate.

US patent 3 938 997 describes a developer for the fast development of high-contrast products of the microfilm type. This developer comprises three developing agents: the first is a ferrous iron chelate, the second is a compound of the ascorbic acid type, the third is Phenidone, glycine, hydroxylamine sulfate etc. Developing solutions are obtained which can be easily concentrated.

European patent 0 588 408 describes a developing composition comprising a main developer of the ascorbic acid type and a mixture of two co-developers of the phenidone type selected from Phenidone-A, Phenidone-B, Dimezone and Dimezone-S. The developing composition enables an improved sensitometric stability to be obtained which does not depend on the reduction of the pH level observed during continuous processing without regeneration. The examples show that this developer is used for developing microfilms.

Patent application WO 95/00881 describes stable developers adapted to the fast development of graphic art films, comprising ascorbic acid or a derivative of the sugar type or an alkaline salts thereof, and a compound of the 3-pyrazolidinone or aminophenol type.

US patent 5 264 323 describes compositions for the development of graphic arts films comprising ascorbic acid or an isomer thereof and a compound of the 3-pyrazolidinone or aminophenol type.

European patent 0 461 783 describes a developing composition comprising ascorbic acid or a derivative thereof,

a 3-pyrazolidinone, sulfite or bisulfite and sodium sulfate or glutaraldehyde, which can be used for the development of medical X-ray films.

Thus, one of the objects of the present invention is a composition for the development of silver halides photographic products, said composition comprising a first silver halide developing agent and a co-developing agent and this composition is characterised in that the co-developing agent corresponds to the general formula:

(I) 

where R^1 and R^2 each separately represent a substituted or non-substituted alkyl group; or a group A-$(X)_p$-A-sol; R^3 to R^7 in formula (I) each separately represent hydrogen, an alkyl, substituted or non-substituted alkoxy or substituted or non-substituted aryloxy group or a group represented by the formula:

$$(X)_p - A - (Sol)$$

where p = 0 or 1;
X represents a divalent group chosen from

$$-O-, -S-, -NR^8-$$

where R^8 = H, alkyl or A-(Sol);
A represents a divalent group chosen from - $(CH_2)_q$-,



where q is between 0 and 5, and y is between 1 and 3; (Sol) is a solubilising group chosen from:
CO_2H, SO_3H, $NHSO_2R^{10}$, SO_2NH_2, SO_2NHR^{10}, polyhydroxyalkyl,



where R^{10} is alkyl or aryl, R^{11} is OH, alkyl or aryl and R^{12} is hydrogen, alkyl or aryl;
with the additional condition that at least one of the radicals R^1 to R^7 must contain a (SOL) group and that $(X)_p$-A-(SOL) cannot represent an ethyl methylsulphonamide radical.

The co-developing agents defined herein have an improved solubility in an aqueous alkaline medium without their superadditivity effect being impaired.

Another object of the invention is a developing composition comprising a developing agent for silver halides se-

lected from the reductones or the compounds of the ascorbic acid type and at least one co-developing agent which is one of the compounds of the 3-pyrazolidinone type described herein.

The preferred developing compositions comprise a developing agent selected from ascorbic acid, derivatives of the ascorbic acid or sugar type, stereoisomers, diastereoisomers, precursors salts of these compounds and at least one co-developing agent which is one of the compounds of the 3-pyrazolidinone type defined herein.

In the following description, reference will be made to the following figures:

Figure 1, which depicts the sensitometric curves obtained with control developers and with a developer according to the invention comprising ascorbic acid and compound II in a "Slow Access" process for the development of a film of stills.

Figure 2, which depicts the sensitometric curves obtained with a control developer and with a developer according to the invention comprising ascorbic acid and compound VI.

Black and white photographic products can be considered as forming two distinct groups depending on development time. Thus, black and white films designed for motion picture, industrial radiography, and black and white papers are developed relatively slowly. Typical development times are of the order of 1 to 3 minutes for papers and from 4 to 12 minutes for films. The development temperature is between 18 and 27°C but can also be higher. This what is referred to as "Slow Access" in the art. A known developer of the "slow access" type is the Kodak D-76® universal developer in powder form, used for example for the development of black and white films for still photography and which contains hydroquinone and Elon®.

The rapid development systems, also referred to as "rapid access" systems, are used for the development of medical X-ray films, graphic arts films and microfilms. These products are developed using very active solutions. The development time is of the order of 30 seconds or less and the development temperature is around 35°C. A example of the "rapid access" type developer is the Kodak RP X-OMAT® developer used for the development of radiographic films, which comprises hydroquinone and phenidone-A as a co-developer. Other "rapid access" developers comprising ascorbic acid and dimezone-S as co-developer are described in Research Disclosure, August 1993, Article 35249.

The novel compounds of the 3-pyrazolidinone type according to the invention have solubilising groups which are not attached directly to the phenyl ring or to the pyrazolidine ring. According to a preferred embodiment, the 3-pyrazolidinones according to the invention have one of the formulae:







where R^1, R^2, R^8, R^{10} and A have the aforementioned signification.

An example of a compound according to the invention has the formula:



(I)

Another example of a compound according to the invention comprising a solubilising group attached indirectly to the phenyl ring by means of an alkylene group is 2-(4-(4,4'-dimethyl-3-oxo-pyrazolidinyl)phenyl) acetic acid (Compound II):

(II)



Other compounds according to the invention have the formula:



(III)



(IV)



(V)



(VI)



(VII)



(VIII)



(IX)


O
Me
Me
HN
N
NH
SO3Na

(X)


O
Me
Me
HN
N
NH
SO3Na

(XI)


O
CH2OH
CH2OH
HN
N
NH
SO3H

(XII)



(XIII)



(XIV)



(XV)



(XVI)

The developers of the invention preferentially can comprise a first developing agent of the di- and polyhydroxybenzene or the reductone type, and at least one co-developing agent of the 3-pyrazolidinone type as defined above.

The compound according to the invention can be used as the sole co-developing agent or in admixture with other compounds according to the invention or with known aminophenols or phenidones such as Elon®, Phenidone-A, Phenidone-B, Dimezone, Dimezone-S or 4,4-dihydroxymethyl-1-phenyl-5-pyrazolidinone.

The co-developing agent of the 3-pyrazolidinone type can be used in the developing composition at an amount which depends on the photographic product to be processed, the desired effects or the nature of the developing agents. Usually, the amount of co-developing agent can be in the range of from 0.0005 to 0.2 mol./l, or more, and preferably from 0.005 to 0.06 mol./l of ready-to-use solution.

The novel compounds of the 3-pyrazolidinone type according to the invention can be used in developing compositions as "slow access" or "rapid access" co-developers in combination with all known developing agents.

In black and white developing solutions, the developing agent is a compound chosen generally from the di- and polyhydroxybenzenes and reductones. The most widely used dihydroxybenzenes are hydroquinone, catechol and their derivatives. Examples of reductones include ene-diols, ene-animols, ene-diamines, thio-enols and enamine-thiols. The most widely used reductones are cited in US patent 2 691 589, in particular ascorbic acid, its stereoisomers, diastereoisomers and derivatives of the sugar type.

While hydroquinone can be used as the first developing agent in the developing compositions according to the invention, the ascorbic acid and sugar-type derivatives, stereoisomers, diastereoisomers, precursors and salts thereof are preferred.

For example, it is possible to use as a developing agent D-isoascorbic (or erythorbic) acid, L-ascorbic acid and their salts such as sodium or potassium ascorbate or erythorbate; sugar-type derivatives of ascorbic acid such as D-glucoascorbic acid, 6-desoxyl-1-ascorbic acid, L-rhamnoascorbic acid, L-fucoascorbic acid, D-glucoheptoascorbic acid, sorboascorbic acid, ω-lactoascorbic acid, maltoascorbic acid, 1-araboascorbic acid, L-glucoascorbic acid, D-galactoascorbic acid, L-guloascorbic acid and L-alloascorbic, imino-ascorbic and L-gluco-ascorbic acid; the ketal derivatives of ascorbic and isoascorbic acid, for example 5,6-isopropylene ascorbic acid; and the precursors of ascorbic acid, for example, methyl-2-ketogluconate or a mixture of these.

In practice, a quantity of developing agent of the hydroquinone or ascorbic acid type is used in the developing composition which is between 0.1 and 0.4 mol./l or more, and preferably between 0.15 and 0.30 mol./l of ready-to-use solution.

The developing composition according to the invention can contain, in addition to the developing agent and co-developer, numerous conventional additives such as silver halide solvents, alkaline bases, organic or inorganic antifog agents, pH buffers, antioxidants, sequestering agents, agents for controlling swelling, hardeners and wetting agents. Within the scope of the invention, the developing composition is amenable to numerous variations accessible to persons skilled in the art in accordance with the envisaged application. These developers can be in the form of a concentrated liquid or in solid form such as powders, tablets or granules, which can be respectively diluted or dissolved in water to obtain the ready-to-use solution.

The compounds according to the invention have an improved solubility compared with known phenidones. Surprisingly, the presence of these solubilising groups which are not attached directly to the phenyl ring or to the pyrazolidine ring do not cause the large decrease in superadditivity observed in the article in Zhurnal Nauchnoi i Prikladnoi Fotografii i kinematografii already cited. On the contrary, the developing solutions comprising these compounds as co-developers have a satisfactory photographic activity.

In addition, the developing agents based on ascorbic acid are also advantageous because they have little tendency to form silver sludges or to cause metallic silver to be deposited on the equipment.

These developing solutions according to the invention can be used for developing black and white products, such as graphic art products, radiographic products, black and white photographic papers or microfilms or for the black and white development stage of reversible colour films and papers.

The invention is illustrated by the following examples:

EXAMPLES

Example 1

Synthesis of 2-(4-(4,4'-dimethyl-3-oxopyrazolidinyl)phenyl) acetic acid (Compound II)

To a suspension of 4-nitrophenylacetic acid (14.9 g, 0.1 mol) and benzyl alcohol (12 g, 0.11 mol) in 230 ml of toluene, p-toluene sulphonic acid monohydrate (0.5 g) is added at room temperature whilst stirring. The solution is heated to reflux under Dean and Stark conditions for around 22 hours. The solvent is eliminated under reduced pressure and the residual solid is recrystallised in a mixture of toluene and petroleum. After vacuum drying, 21 g (77.5%) of benzyl 4-nitrophenyl acetate (compound 1) is isolated in the form of a whitish solid.

A suspension of compound (1) (5 g, 18.45 mmol) is heated in a mixture of acetic acid (45 ml) and water (5 ml) over a steam bath until the solid dissolves. Iron powder (6 g, 105 mmol) is added in portions over a period of around 10 minutes. Heating is continued for another 1.5 hours after the end of the addition. The hot reaction mixture is poured into water (200 ml) whilst rapidly stirring, and the mixture is extracted in its entirety with some ethyl acetate (2 x 200 ml). The combined organic extracts are washed with brine (200 ml) and dried on magnesium sulphate and the solvent is evaporated under reduced pressure in order to obtain a yellow oil (5.8 g). The raw product is dissolved in acetonitrile (70 ml) and gaseous HCl is passed into the solution to saturation point. The solid is collected by filtration and is dried under vacuum in order to obtain 3.4 g (65.4%) of benzyl 4-aminophenylacetate hydrochloride (compound 2) in the form of a cream-coloured solid.

A suspension of compound (2) (7.9 g, 28.5 mmol) in a mixture of concentrated HCl (32 ml) and water (11 ml) is cooled to 0°C. A solution cooled in sodium nitrite ice (2.2 g, 31 mmol) in water (6.5 ml) is added to the above suspension for a period of 15 minutes, keeping the internal temperature below 5°C. The mixture is stirred for 10 minutes more before adding a mixture of tin II chloride (23.8 g, 126.2 mmol), concentrated HCl (130 ml) and water (260 ml) at room temperature, stirring rapidly. The solid obtained is collected by filtration and the moist solid is titrated with acetonitrile (150 ml), filtered and dried under vacuum in order to obtain 5.9 g (71%) of benzyl 4-hydrazinophenylacetate hydrochloride (compound 3).

To a solution of compound (3) (7.7 g, 26.3 mol) in dry pyridine (60 ml), 3-chloropivaloyl chloride (4.0 g, 25.5 mol) is added drop by drop for 10 minutes at around 5°C with stirring. The mixture is then stirred at room temperature for 20 hours before being poured into a mixture of ice and water (600 ml) and concentrated HCl (60 ml). A yellow solid is collected by filtration, washed with water and dried under vacuum on phosphorus pentoxide (8.4 g). The raw product is titrated with cold diethyl ether (80 ml), filtered and dried in air in order to obtain 7.2 g (81%) of benzyl 2-(4-(4,4'-dimethyl-3-oxopyrazolidinyl)phenyl acetate (compound 4) in the form of a cream-coloured solid.

A solution of compound (4) (3.5 g, 10.35 mmol) is hydrogenated on palladium-containing carbon (0.3 g, 10% Pd) in tetrahydrofuran (270 ml) under 34 atmospheres of hydrogen at room temperature for 24 hours. The catalyst is eliminated by filtration on a kieselguhr buffer and the filtrate evaporated under reduced pressure in order to obtain a yellow gum. The raw product is titrated with diethylether (100 ml), filtered and dried under vacuum. 2.13 g (83%) of 2-(4-(4,4'-dimethyl-3-oxopyrazolidinyl)phenyl) acetic acid (compound II) is obtained in the form of a cream-coloured solid.

Example 2

Synthesis of compound VI

3-chloropivaloyl chloride (18.1 g, 116.5 mmol) is added to a suspension of 3-nitrophenylhydrazine hydrochloride (22.1 g, 116.5 mmol) in anhydrous pyridine (250 ml). The addition is carried out at 5°C with stirring. This addition takes 35 minutes. Stirring is then continued at +5°C for 1 hour, and then at room temperature for a further hour, after which the mixture is heated to reflux under nitrogen for 20 hours. It is cooled to room temperature, and then the suspension is poured into a vigorously stirred mixture of water and ice (2.75 l) and concentrated hydrochloric acid (250 ml). A yellow solid is formed which is collected by filtration and washed in water (2 l). After drying under vacuum and on P_2O_5, 24.9 g of a yellow solid, 4,4-dimethyl-1-(3-nitrophenyl-pyrazolidine-3-one), is collected; yield 91%.

A suspension of this product (24.8 g; 105.5 mmol) in tetrahydrofuran (500 ml) is hydrogenated under 32 atmos-

pheres of H_2 at 30°C for 24 hours in the presence of palladium on a substrate of carbon (2 g at 10%). Magnesium sulphate (around 5 g) is added and the mixture is filtered under suction through a kieselguhr buffer. The filtrate is evaporated dry, producing a brown oil. A mixture of t-butanol (250 ml) and anhydrous THF (50 ml) is added. This solution is heated to reflux under an atmosphere of dry nitrogen, while a solution of 1,3-propanesultone (12.9 g; 105.5 mmol) in anhydrous THF (30 ml) is added drop by drop over around 40 minutes, whilst stirring. The mixture is heated to reflux under nitrogen for a further 20 hours. After cooling to room temperature, a solid forms which is collected by filtration and then dissolved again in acetonitrile (300 ml). This is filtered again and, after drying under vacuum, a cream-coloured solid (29.8 g) is obtained. By recrystallisation in a mixture of acetonitrile and ethanol and then drying under vacuum, 3-(4,4-dimethyl-3-oxo-pyrazolidine-1-yl)phenylamino-1-propanesulphonic acid (12.3 g; yield 36%) is obtained.

Example 3

Slow access - Ascorbic acid developing agent Co-developer Compound II

In this example a black and white still film is exposed at 2850°K with a colour-corrective filter for 1/25 of a second through a stepped sensitometric wedge. This film is developed for 12 minutes, whilst stirring, at 33°C, fixed for 5 minutes in T-Max® fixative and washed for 10 minutes under running water.

A developing solution according to the invention comprising ascorbic acid as a developing agent and compound II as a co-developer is evaluated by comparing it with a commercially available developer Kodak D-76® which comprises hydroquinone and Elon® and with a second control which comprises ascorbic acid and Elon®.

All the developers contain 45 mmol/l of developing agent, 12 mmol/l of co-developer and 126 g/l of potassium sulphite and the pH is adjusted to 8.6 by potassium carbonate.

Figure 1 gives the D(Log E) sensitometric curves obtained for a development time of 12 minutes at 33°C. It can be see that at 33°C compound II gives a sensitometric curve very close to that obtained when Elon® is associated with hydroquinone.

Example 4

Rapid access - Ascorbic acid developing agent Co-developer Compound VI

In this example a radiographic film is exposed for 1/50 of a second on both faces through a filter simulating the re-emission of a green screen at 2850°K. This film is developed for 3 minutes at room temperature, manually reproducing the conditions of RP X-OMAT® processing machines, fixed for 2 minutes and washed for 3 minutes in running water.

In this example the control used is the developer whose formula is given in Research Disclosure of August 1993, Article 35249, already cited:

ascorbic acid	32.0 g/l
dimezone-S (HMMP)	2.5 g/l
benzotriazol	0.2 g/l
KBr	4.0 g/l
K_2SO_3	50.0 g/l
K_2CO_3	100.0 g/l
Na DTPA	4.3 g/l
pH	10.2

* DTPA solution with 40% diethylenetriaminepentacetic acid.

The developer according to the invention comprises the same constituents, except that compound VI replaces Dimezone-S.

Figure 2 gives the sensitometric curve obtained with compound VI associated with ascorbic acid.

The sensitometric curve is very similar to that obtained with dimezone-S associated with ascorbic acid.

Claims

1. Composition for the development of silver halide photographic products comprising a first developing agent for silver halide and a co-developer, characterised in that the co-developer has the formula:

(I)



where R^1 and R^2 each separately represent a substituted or non-substituted alkyl group, or a group $A-(X)_p-A$-sol; R^3 to R^7 in formula (I) each separately represent hydrogen, an alkyl, substituted or non-substituted alkoxy or substituted or non-substituted aryloxy group or a group represented by the formula:

$$(X)_p - A - (Sol)$$

where p = 0 or 1;
X represents a divalent group chosen from

$$-O-, -S-, -NR^8-$$

where R^8 = H, alkyl or A-(Sol);
A represents a divalent group chosen from - $(CH_2)_q$-,



where q is between 0 and 5, and y is between 1 and 3;
(Sol) is a solubilising group chosen from:
CO_2H, SO_3H, $NHSO_2R^{10}$, SO_2NH_2, SO_2NHR^{10}, polyhydroxyalkyl,



where R^{10} is alkyl or aryl, R^{11} is OH, alkyl or aryl and R^{12} is hydrogen, alkyl or aryl;
with the additional condition that at least one of the radicals R^1 to R^7 must contain a (SOL) group and that $(X)_p$-A-(SOL) cannot represent an ethyl methylsulphonamide radical.

2. Composition according to Claim 1, characterised in that the co-developer is chosen from the class consisting of



where A, R^8, R^{10} have the signification indicated in Claim 1.

3. Composition according to Claim 1 or 2, in which the first developing agent is chosen from the class consisting of hydroquinone and the derivatives of hydroquinone.

4. Composition according to one of Claims 1 to 3, in which the first developing agent is chosen from the class consisting of ascorbic acid, its derivatives of the sugar type, as well as their stereoisomers, diastereoisomers and precursors and salts thereof.


DENSITY
4.0
3.0
2.0
1.0
0.0
2
4
6
8
10
12
14
16
18
20
Log E
D-76 12 minutes
AA + elon 12 minutes
AA + (II) 12 minutes

Fig. 1



Fig. 2

European Patent Office

EUROPEAN SEARCH REPORT

Application Number
EP 97 42 0091

DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	CLASSIFICATION OF THE APPLICATION (Int.Cl.6)
Y	US 4 266 002 A (MCCREARY ET AL.) * column 1, line 15 - line 17 * * column 1, line 27 - line 30 * * column 1, line 39 - column 2, line 5 * * column 2, line 59 - line 66 * * column 3; examples 10,11 * * column 6, line 35 - line 37 *	1-4	G03C5/30
Y	US 3 865 591 A (KATZ) * claims 1-5 *	1-4	
			TECHNICAL FIELDS SEARCHED (Int.Cl.6) G03C

The present search report has been drawn up for all claims

Place of search	Date of completion of the search	Examiner
THE HAGUE	21 August 1997	Magrizos, S

CATEGORY OF CITED DOCUMENTS

X : particularly relevant if taken alone
Y : particularly relevant if combined with another document of the same category
A : technological background
O : non-written disclosure
P : intermediate document

T : theory or principle underlying the invention
E : earlier patent document, but published on, or after the filing date
D : document cited in the application
L : document cited for other reasons

& : member of the same patent family, corresponding document

EPO FORM 1503 03.82 (P04C01)

THIS PAGE IS BLANK